ProQR Therapeutics N.V. (PRQR)
| Market Cap | 204.63M -15.2% |
| Revenue (ttm) | 21.05M +7.5% |
| Net Income | -48.03M |
| EPS | -0.46 |
| Shares Out | 141.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 784,704 |
| Open | 1.480 |
| Previous Close | 1.470 |
| Day's Range | 1.440 - 1.485 |
| 52-Week Range | 1.330 - 3.100 |
| Beta | 0.20 |
| Analysts | Strong Buy |
| Price Target | 7.78 (+436.55%) |
| Est. Earnings | Nov 5, 2026 |
About PRQR
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metab... [Read more]
Financial Performance
In 2025, ProQR Therapeutics's revenue was 16.35 million, a decrease of -16.36% compared to the previous year's 19.55 million. Losses were -42.18 million, 51.9% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for PRQR stock is "Strong Buy." The 12-month stock price target is $7.78, which is an increase of 436.55% from the latest price.
News
ProQR Therapeutics management to meet with Oppenheimer
Meeting to be held in Dallas on October 20 hosted by Oppenheimer.
ProQR Therapeutics management to meet with Oppenheimer
Meeting to be held in Denver on October 15 and in San Francisco on October 16 hosted by Oppenheimer.
ProQR price target lowered to $8 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ananda Ghosh lowered the firm’s price target on ProQR Therapeutics (PRQR) to $8 from $12 and keeps a Buy rating on the shares following the research and…
ProQR Therapeutics Transcript: Investor update
AX-0810 showed dose-dependent human NTCP engagement across three biomarkers with a favorable safety profile to date. AX-0811 and biliary atresia studies advance toward 2027 readouts, testing whether altered bile acid handling can improve liver health.
ProQR Therapeutics Slides: Investor update
ProQR Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2026.
ProQR Therapeutics Press release: Investor update
ProQR Therapeutics issued a press release on September 30, 2026, disclosing material business information to investors.
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
Appointments support ProQR's strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline AX-0811, the first ProQR program identified thro...
ProQR Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Clinical dosing began for AX-0811, with five trial readouts expected across four programs in the next year. AI-driven advances have improved editing efficiency and accelerated pipeline expansion, with new data and regulatory milestones anticipated for cholestatic, MPS I, and lean MASH programs.
ProQR Therapeutics doses first participant in AX-0811 clinical trial
ProQR Therapeutics (PRQR) announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers.
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative R...
ProQR to Participate in Upcoming Investor Conferences in September 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Therapeutics initiated with a Buy at BofA
BofA analyst Alec Stranahan initiated coverage of ProQR Therapeutics (PRQR) with a Buy rating and $8 price target The firm says AX-0810 provides the first human validation of Axiomer, ProQR’s…
ProQR Announces Second Quarter 2026 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative R...
ProQR Therapeutics Earnings release: Q2 2026
ProQR Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
ProQR Therapeutics registers to sell 3.03M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.03M ordiary shares. The company is not selling any shares under…
ProQR Therapeutics Registration statement: Registration filing
ProQR Therapeutics filed a registration statement on July 6, 2026, providing details about a securities offering with the SEC.
ProQR Therapeutics price target lowered to $10 from $14 at Raymond James
Raymond James lowered the firm’s price target on ProQR Therapeutics (PRQR) to $10 from $14 and keeps a Strong Buy rating on the shares. Based on the thesis that early…
ProQR Therapeutics price target lowered to $10 from $11 at JonesResearch
JonesResearch analyst Catherine Novack lowered the firm’s price target on ProQR Therapeutics (PRQR) to $10 from $11 and keeps a Buy rating on the shares. The firm cites the company’s…
ProQR Therapeutics price target lowered to $3 from $4 at Chardan
Chardan analyst Keay Nakae lowered the firm’s price target on ProQR Therapeutics (PRQR) to $3 from $4 and keeps a Buy rating on the shares. The company reported target engagement…
ProQR Therapeutics Slides: Conference presentation
ProQR Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering
ProQR Therapeutics (PRQR) announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares at an offering price of $1.81 per share (the “Offering Price”), for total gr...
ProQR Therapeutics announces positive Phase 1 data for AX-0810
ProQR Therapeutics (PRQR) announced positive target engagement data from its ongoing Phase 1 clinical study evaluating AX-0810, the company’s first investigational Axiomer RNA editing oligonucleotide,...
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through...
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR or the Company), a clinical-stage biotechnology company dedicated to changing li...
ProQR Announces First Quarter 2026 Operating and Financial Results
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDU...